Youngene Therapeutics Announced Today: Dr. Pablo Lapuerta (CMO) will give a speech at the 58th European DiabetesAnnual Conference which is held in Stockholm, Sweden next week. His speech's time slot is from 6pm to 7pm on Sep.21, Beijing time. He will release the data of clinical phase ll study of YG1699.And a Key Opinion Leader seminar will beheld on the next day as well.

The T1DM phase 2 study of YG1699 has been completed successfully last month.This was a three-crossover,randomized, double-blind trial. It had a head-to-head comparison with DapaglifiozinI/Forxiga in this study. The study'sresults showed that YG1699 was not only superior to DAPA in hypoglycemic, but was also significantly superior to DAPAin controlling postprandial blood glucose and continuously increasing endogenous GLP1.

Recently the SGLT2 class has shown advantages not only in diabetes, but also in the treatment of heart failure andkidney disease. However, most recent researches have shown that due to the introduction of SGLT1, the efficacy andsafety of SGLT1+2 in these indications are better than SGLT2 products, and YG1699 has the potential to become thebest-in-class SGLTi product.

About Youngene Therapeutics:

Youngene Therapeutics is a clinical phase 2 stage pharmaceutical company. Mainly focusing on metabolic diseases.YG1699,one of the leading product has completed Phase l and Phasell study in USA, and its Chinese clinical bridgingstudy will be completed soon.